# MUC1 VNTR Mutation Extension Plan

**Date:** 2025-10-18
**Purpose:** Extend MucOneUp mutation configuration with clinically-validated pathogenic mutations and synthetic benign mutations for comprehensive benchmarking of variant calling tools.

---

## Executive Summary

This plan outlines the integration of **clinically-validated ADTKD-MUC1 mutations** from Vrbacká et al. 2025 preprint and the design of **4 focused synthetic benign mutations** for benchmarking variant callers.

**Key Findings:**
1. **9 real pathogenic mutation types** identified in 52 VNTR alleles (Vrbacká et al. 2025)
2. **dupC (59dupC/27dupC)** accounts for 93.5% of families (Olinger 2020) and 85% (42/52 alleles in Vrbacká 2025)
3. **insCCCC** is REAL (not synthetic) - maps to 56_59dupCCCC from Vrbacká 2025 (1 family)
4. **6 NEW real mutations** need to be added from Vrbacká 2025 preprint
5. **4 synthetic benign mutations** selected for maximum specificity testing coverage (reduced from 15+)
6. **ins16bp** is a 16-base duplication (C:42_57dupGGGCTCCACCGCCCCC) - rare complex variant

**Validation Strategy:**
- All mutations must be validated using ORF analysis to verify frameshift status
- Pathogenic mutations MUST produce toxic MUC1fs protein
- Benign mutations MUST NOT produce frameshift

**Goal:** Create a comprehensive, citation-backed mutation database that tests both sensitivity (detecting real pathogenic variants) and specificity (distinguishing pathogenic from benign variants).

---

## 1. Background: ADTKD-MUC1 Pathogenesis

### 1.1 The Toxic Frameshift Mechanism

**Key Pathogenic Principle:**
- ADTKD-MUC1 is caused by frameshift mutations in the MUC1 VNTR region
- **ALL pathogenic variants produce the SAME frameshift protein (MUC1fs)**
- The frameshift creates a novel 20-amino acid repeat sequence
- MUC1fs accumulates in the ER-Golgi intermediate compartment (ERGIC)
- Accumulation triggers unfolded protein response (UPR) → cellular stress → apoptosis → kidney failure

### 1.2 Frameshift Rules

**Pathogenic (Frameshift):**
- Insertions: +1, +2, +4, +5, +7, +8, ... (NOT divisible by 3)
- Deletions: -1, -2, -4, -5, -7, -8, ... (NOT divisible by 3)
- Complex indels that result in net change not divisible by 3

**Benign (In-Frame):**
- Insertions: +3, +6, +9, +12, ... (divisible by 3)
- Deletions: -3, -6, -9, -12, ... (divisible by 3)
- Complex indels that result in net change divisible by 3
- SNPs that don't alter reading frame
- Natural VNTR repeat number polymorphism (20-125 repeats)

### 1.3 The Critical Cytosine Stretch

**Structure:** 7-cytosine heptanucleotide tract (7C → wild-type)
**Position:** Nucleotides 53-59 (or positions 27 in alternative nomenclature)
**Pathogenic Mutation:** 8-cytosine tract (8C → dupC/insC)
**Frequency:** ~93-95% of all ADTKD-MUC1 cases worldwide

---

## 2. Literature Review: Known Pathogenic Mutations

### 2.1 Clinically-Validated Frameshift Mutations

Based on recent literature (Olinger et al., Vrbacká et al. 2025, and others):

| Mutation Name | Type | Position(s) | Sequence Change | Frequency | Source |
|---------------|------|-------------|-----------------|-----------|--------|
| **27dupC / 59dupC** | Insertion | 53-59 (7C tract) | C→CC (creates 8C) | 93-95% | Multiple studies |
| **28dupA** | Insertion | 28 | A→AA | ~3% | Olinger et al. |
| **26_27insG / c.427_428insG** | Insertion | 26-27 | insG | ~2% | Multiple studies |
| **23delinsAT** | Delins | 23-24 | del+insAT | ~1% | Olinger et al. |
| **41insC** | Insertion | 41 | insC | Rare/Novel | Danish study 2025 |
| **16bp insertion** | Insertion | Variable | 16bp duplication | Rare/Novel | Danish study 2025 |
| **c.428dupC (alternative)** | Insertion | Alternative nomenclature for dupC | - | - | HGVS |

### 2.2 Additional Rare Frameshift Mutations

From Vrbacká et al. (2025) - **9 distinct types of frameshift mutations** identified across 52 distinct mutated VNTR alleles:
- Various single nucleotide insertions (A, G, T, C) at different positions
- Small deletions (1-2 bp)
- Complex indels
- Exact sequences and positions need mapping from full paper

### 2.3 Current MucOneUp Mutations - Gap Analysis

**Currently Implemented:**
```json
"dupC": insertion C at 60-61          → REAL: Maps to 59dupC/27dupC (Kirby 2013; Olinger 2020: 93.5%)
"insCCCC": insertion CCCC at 60-61    → REAL: Maps to 56_59dupCCCC (Vrbacká 2025: 1 family)
"insG": insertion G at 59-60          → REAL: Maps to 26_27insG (Olinger 2020: 2.2%, 2 families)
"dupA": insertion A at 60-61          → REAL: Maps to 60dupA/28dupA (Olinger 2020: 3.2%, 3 families; Vrbacká 2025)
"delinsAT": delete_insert AT at 54-56 → REAL: Maps to 23delinsAT (Olinger 2020: 1.1%, 1 family)
"bigDel": deletion 1-26               → SYNTHETIC (test mutation)
"snpA_testing": replace at 2          → SYNTHETIC (test mutation)
```

**Missing from Vrbacká et al. 2025 Catalog:**
- ✗ 23dupC (2 families, A/E repeats) - different from 23delinsAT
- ✗ 58_59insG (2 families, B/X repeats) - different from our existing insG at 59-60
- ✗ 54_55insG (1 family, bJ repeat)
- ✗ 54_55insA (1 family, aH repeat)
- ✗ 18_31del (1 family, X repeat)
- ✗ 42_57dup16bp (1 family, C repeat)
- ✗ Benign control mutations (in-frame indels for specificity testing)

---

## 3. New Mutations to Implement

### 3.1 Additional Pathogenic Mutations from Vrbacká et al. 2025

All mutations below are **REAL** pathogenic variants identified in patient families.

**Mutation: insC_pos23** (formerly 23dupC, A:/E:23dupC)
```json
{
  "allowed_repeats": ["A", "E"],
  "strict_mode": true,
  "changes": [{
    "type": "insert",
    "start": 23,
    "end": 24,
    "sequence": "C"
  }],
  "type": "real",
  "citation": {
    "authors": "Vrbacká A, Přistoupilová A, Kidd KO, et al.",
    "year": 2025,
    "journal": "bioRxiv",
    "doi": "10.1101/2025.09.06.673538",
    "pmid": null,
    "title": "Long-Read Sequencing of the MUC1 VNTR",
    "note": "Identified in 2 families (Table 1)"
  }
}
```
**Rationale:** Real pathogenic mutation from Vrbacká et al. 2025. Cytosine insertion at position 23 in A or E repeat units. +1 frameshift. Affects different position than existing mutations.

**Mutation: insG_pos58** (formerly 58_59insG)
```json
{
  "allowed_repeats": ["B", "X"],
  "strict_mode": true,
  "changes": [{
    "type": "insert",
    "start": 58,
    "end": 59,
    "sequence": "G"
  }],
  "type": "real",
  "citation": {
    "authors": "Vrbacká A, Přistoupilová A, Kidd KO, et al.",
    "year": 2025,
    "journal": "bioRxiv",
    "doi": "10.1101/2025.09.06.673538",
    "pmid": null,
    "note": "Identified in 2 families"
  }
}
```
**Rationale:** Real pathogenic mutation. Guanine insertion at position 58-59 in B or X repeat units. +1 frameshift.

**Mutation: insG_pos54** (formerly 54_55insG in bJ repeat)
```json
{
  "allowed_repeats": ["bJ"],
  "strict_mode": true,
  "changes": [{
    "type": "insert",
    "start": 54,
    "end": 55,
    "sequence": "G"
  }],
  "type": "real",
  "citation": {
    "authors": "Vrbacká A, Přistoupilová A, Kidd KO, et al.",
    "year": 2025,
    "journal": "bioRxiv",
    "doi": "10.1101/2025.09.06.673538",
    "pmid": null,
    "note": "Identified in 1 family"
  }
}
```
**Rationale:** Real pathogenic mutation. Guanine insertion at position 54-55 in bJ repeat unit. +1 frameshift. Rare variant.

**Mutation: insA_pos54** (formerly 54_55insA in aH repeat)
```json
{
  "allowed_repeats": ["aH"],
  "strict_mode": true,
  "changes": [{
    "type": "insert",
    "start": 54,
    "end": 55,
    "sequence": "A"
  }],
  "type": "real",
  "citation": {
    "authors": "Vrbacká A, Přistoupilová A, Kidd KO, et al.",
    "year": 2025,
    "journal": "bioRxiv",
    "doi": "10.1101/2025.09.06.673538",
    "pmid": null,
    "note": "Identified in 1 family"
  }
}
```
**Rationale:** Real pathogenic mutation. Adenine insertion at position 54-55 in aH repeat unit. +1 frameshift. Rare variant.

**Mutation: del18_31** (formerly 18_31del)
```json
{
  "allowed_repeats": ["X"],
  "strict_mode": true,
  "changes": [{
    "type": "delete",
    "start": 18,
    "end": 32
  }],
  "type": "real",
  "citation": {
    "authors": "Vrbacká A, Přistoupilová A, Kidd KO, et al.",
    "year": 2025,
    "journal": "bioRxiv",
    "doi": "10.1101/2025.09.06.673538",
    "pmid": null,
    "note": "Identified in 1 family"
  }
}
```
**Rationale:** Real pathogenic mutation. 14bp deletion at positions 18-31 in X repeat unit. Frameshift (14 = -2 reading frame). Rare variant.

**Mutation: ins16bp** (C:42_57dupGGGCTCCACCGCCCCC)
```json
{
  "allowed_repeats": ["C"],
  "strict_mode": true,
  "changes": [{
    "type": "insert",
    "start": 57,
    "end": 58,
    "sequence": "GGGCTCCACCGCCCCC"
  }],
  "type": "real",
  "citation": {
    "authors": "Vrbacká A, Přistoupilová A, Kidd KO, et al.",
    "year": 2025,
    "journal": "bioRxiv",
    "doi": "10.1101/2025.09.06.673538",
    "pmid": null,
    "title": "Long-Read Sequencing of the MUC1 VNTR",
    "note": "16bp duplication at positions 42-57 (C:42_57dupGGGCTCCACCGCCCCC), identified in 1 family"
  }
}
```
**Rationale:** Real pathogenic mutation from Vrbacká et al. 2025. Duplication of positions 42-57 (exactly 16 bases: GGGCTCCACCGCCCCC) in C repeat unit. +1 frameshift (16 mod 3 = 1). Rare complex variant representing tandem duplication within the repeat.


### 3.2 Benign/Non-Pathogenic Mutations (For Specificity Testing)

**IMPORTANT**: These are **SYNTHETIC** mutations designed to test variant caller specificity. They maintain the reading frame (divisible by 3) and should NOT produce toxic MUC1fs protein.

**Selection Rationale**: These 4 mutations provide maximum coverage for specificity testing while keeping it simple:
1. In-frame insertion in C-stretch (directly discriminates from dupC)
2. Larger in-frame insertion in C-stretch (discriminates from +4, +5 frameshifts)
3. In-frame deletion in C-stretch (tests deletion specificity)
4. In-frame deletion outside C-stretch (tests different sequence context)

---

**Mutation: insCCC_benign** (+3 in-frame)
```json
{
  "allowed_repeats": ["X"],
  "strict_mode": true,
  "changes": [{
    "type": "insert",
    "start": 60,
    "end": 61,
    "sequence": "CCC"
  }],
  "type": "synthetic",
  "citation": null,
  "note": "Designed for benchmarking specificity"
}
```
**Rationale:** 7C→10C tract. In-frame (+3) insertion at EXACT same location as pathogenic dupC (+1). Critical test: can variant callers distinguish +1 (pathogenic) from +3 (benign) in homopolymer?

---

**Mutation: insCCCCCC_benign** (+6 in-frame)
```json
{
  "allowed_repeats": ["X"],
  "strict_mode": true,
  "changes": [{
    "type": "insert",
    "start": 60,
    "end": 61,
    "sequence": "CCCCCC"
  }],
  "type": "synthetic",
  "citation": null,
  "note": "Designed for benchmarking specificity"
}
```
**Rationale:** 7C→13C tract. Larger in-frame (+6) insertion. Tests discrimination from insCCCC (+4, pathogenic) and insCCCCC (+5, pathogenic). Can callers accurately determine homopolymer length?

---

**Mutation: delCCC_benign** (-3 in-frame)
```json
{
  "allowed_repeats": ["X"],
  "strict_mode": true,
  "changes": [{
    "type": "delete",
    "start": 54,
    "end": 57
  }],
  "type": "synthetic",
  "citation": null,
  "note": "Designed for benchmarking specificity"
}
```
**Rationale:** 7C→4C tract. In-frame (-3) deletion in C-stretch. Tests if callers can correctly identify benign deletions in homopolymer tracts. Complements insertion tests.

---

**Mutation: del3bp_pos30_benign** (-3 in-frame, outside C-stretch)
```json
{
  "allowed_repeats": ["X", "A", "B"],
  "strict_mode": true,
  "changes": [{
    "type": "delete",
    "start": 30,
    "end": 33
  }],
  "type": "synthetic",
  "citation": null,
  "note": "Designed for benchmarking specificity"
}
```
**Rationale:** In-frame (-3) deletion OUTSIDE cytosine tract. Tests sequence context dependency. Different GC content and no homopolymer. Should be clearly benign.

---

## 4. Implementation Strategy

### 4.1 Phase 1: Position Mapping (CRITICAL)

**Action Required:**
1. **Map literature positions to MucOneUp X repeat positions**
   - Literature uses various nomenclatures (HGVS, genomic, repeat-relative)
   - MucOneUp uses 0-based indexing within 60bp repeat units
   - Need to identify the exact 7C tract position in the X repeat sequence

2. **Analyze X repeat sequence:**
```
Position:  0         10        20        30        40        50        60
X repeat:  GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCCCCCCA
```

   - Find the 7C tract: Appears to be at positions **48-54** (CCCCCCC)
   - Clinical position 53-59 may refer to different coordinate system
   - **VERIFY THIS CAREFULLY** before implementing mutations

3. **Create position mapping table:**
   | Clinical Position | MucOneUp Position | Feature |
   |------------------|-------------------|---------|
   | 23-24 | ? | delinsAT site |
   | 26-27 | ? | insG site |
   | 28 | ? | dupA site |
   | 41 | ? | novel insC site |
   | 53-59 (7C tract) | 48-54? | dupC site (verify!) |

### 4.2 Phase 2: Validate Existing Mutations

**Action Required:**
1. Review existing mutations against clinical literature
2. Verify position accuracy
3. Update documentation with clinical correlates
4. Add literature references to each mutation

### 4.3 Phase 3: Implement New Pathogenic Mutations

**Priority Order:**
1. ✓ **High Priority (Common Clinical Variants):**
   - Verify existing dupC maps to 27dupC
   - Verify existing dupA maps to 28dupA
   - Verify existing insG maps to 26_27insG
   - Verify existing delinsAT maps to 23delinsAT

2. ✓ **Medium Priority (Novel 2025 Variants):**
   - Implement insC_pos41
   - Implement ins16bp (need exact sequence from paper)

3. ✓ **Lower Priority (Synthetic Frameshift Variants):**
   - Additional positions for sensitivity testing
   - Different nucleotides (T, G) at various positions

### 4.4 Phase 4: Implement Benign Mutations

**Priority Order:**
1. ✓ **High Priority (In-frame C-stretch variants):**
   - insCCC_benign (+3)
   - insCCCCCC_benign (+6)
   - delCCC_benign (-3)

2. ✓ **Medium Priority (In-frame variants elsewhere):**
   - del3bp_pos30_benign
   - del6bp_pos20_benign

3. ✓ **Lower Priority (Complex benign variants):**
   - delins variants
   - compound mutations
   - silent SNPs

### 4.5 Phase 5: Validation & Testing with ORF Analysis

**CRITICAL VALIDATION STEP**: All mutations must be validated using ORF prediction to verify frameshift status.

**Action Required:**

1. **Generate test sequences for ALL mutations**
   ```bash
   # For each pathogenic mutation
   for mutation in dupC insCCCC insC_pos23 insG_pos58 insG_pos54 insA_pos54 del18_31 ins16bp; do
     muconeup --config config.json simulate \
       --out-base validate_${mutation} \
       --out-dir validation/ \
       --fixed-lengths 60 \
       --mutation-name ${mutation} \
       --mutation-targets 1,30 \
       --output-orfs \
       --orf-min-aa 50
   done

   # For each benign mutation
   for mutation in insCCC_benign insCCCCCC_benign delCCC_benign del3bp_pos30_benign; do
     muconeup --config config.json simulate \
       --out-base validate_${mutation} \
       --out-dir validation/ \
       --fixed-lengths 60 \
       --mutation-name ${mutation} \
       --mutation-targets 1,30 \
       --output-orfs \
       --orf-min-aa 50
   done
   ```

2. **Verify frameshift vs in-frame using ORF analysis:**

   **Expected Results for PATHOGENIC mutations:**
   - ORF prediction should show **FRAMESHIFT**
   - Novel amino acid sequence in frameshifted region
   - Should produce MUC1fs toxic protein signature
   - If toxic_protein_detector is available, should flag as toxic

   **Expected Results for BENIGN mutations:**
   - ORF prediction should show **NO FRAMESHIFT**
   - Normal reading frame maintained
   - Should NOT produce toxic protein signature
   - May have minor amino acid changes but frame is preserved

3. **Document ORF validation results:**
   Create `validation_results.tsv`:
   ```
   mutation_name    type         expected_frameshift    observed_frameshift    status    notes
   dupC             real         yes                    yes                    PASS      Produces MUC1fs
   insCCCC          real         yes                    yes                    PASS      +4 frameshift
   insC_pos23       real         yes                    yes                    PASS      +1 frameshift in A/E
   insCCC_benign    synthetic    no                     no                     PASS      In-frame +3
   insCCCCCC_benign synthetic    no                     no                     PASS      In-frame +6
   ...
   ```

4. **Test dual simulation:**
   - Generate normal + mutated pairs
   - Verify FASTA output
   - Compare ORF predictions between normal and mutated

5. **Create benchmarking dataset:**
   - Mix of pathogenic and benign mutations
   - Known ground truth labels
   - Multiple VNTR lengths
   - Different repeat structures
   - Include ORF validation results in metadata

---

## 5. Mutation Nomenclature & Documentation

### 5.1 Naming Convention

**Format:** `{type}_{variant}_{position}_{benign}`

**Examples:**
- `dupC` → pathogenic cytosine duplication (existing)
- `insC_pos41` → pathogenic cytosine insertion at position 41
- `insCCC_benign` → benign in-frame cytosine insertion
- `del3bp_pos30_benign` → benign 3bp deletion at position 30

### 5.2 Documentation Required

For each mutation, document:
1. **Clinical name** (if applicable): e.g., "c.27dupC", "59dupC"
2. **Type**: Insertion, Deletion, Delins, Replace
3. **Position(s)**: Start and end in MucOneUp coordinates
4. **Sequence change**: What changes
5. **Frameshift**: Yes/No
6. **Expected effect**: Pathogenic (MUC1fs) or Benign (in-frame)
7. **Frequency**: If known from literature
8. **Source**: Citation(s)
9. **Rationale**: Why this mutation is included

### 5.3 Metadata in config.json

**Proposed Enhancement - NEW Required Fields:**

All mutations must include:
- **`type`**: "real" (from patient data) or "synthetic" (designed for testing)
- **`citation`**: Full citation object (or null for synthetic)

```json
"mutations": {
  "dupC": {
    "allowed_repeats": ["X"],
    "strict_mode": true,
    "changes": [{
      "type": "insert",
      "start": 60,
      "end": 61,
      "sequence": "C"
    }],
    "type": "real",
    "citation": {
      "authors": "Kirby A, Gnirke A, Jaffe DB, et al.",
      "year": 2013,
      "journal": "Nat Genet",
      "volume": "45",
      "issue": "3",
      "pages": "299-303",
      "pmid": "23396133",
      "doi": "10.1038/ng.2543",
      "title": "Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1",
      "note": "First identification of MUC1 VNTR mutations. Most common ADTKD-MUC1 mutation (85% of families)"
    },
    "metadata": {
      "clinical_name": "c.27dupC / 59dupC",
      "pathogenicity": "pathogenic",
      "frameshift": true,
      "frequency": "85%",
      "description": "Most common ADTKD-MUC1 mutation. Cytosine insertion in 7C tract.",
      "benchmarking_category": "true_positive"
    }
  },
  "insCCCC": {
    "allowed_repeats": ["X"],
    "strict_mode": true,
    "changes": [{
      "type": "insert",
      "start": 60,
      "end": 61,
      "sequence": "CCCC"
    }],
    "type": "real",
    "citation": {
      "authors": "Vrbacká A, Přistoupilová A, Kidd KO, et al.",
      "year": 2025,
      "journal": "bioRxiv",
      "doi": "10.1101/2025.09.06.673538",
      "pmid": null,
      "title": "Long-Read Sequencing of the MUC1 VNTR",
      "note": "56_59dupCCCC mutation identified in 1 family"
    },
    "metadata": {
      "clinical_name": "56_59dupCCCC",
      "pathogenicity": "pathogenic",
      "frameshift": true,
      "frequency": "rare",
      "description": "+4 frameshift in C-stretch. Rare pathogenic variant.",
      "benchmarking_category": "true_positive"
    }
  },
  "insCCC_benign": {
    "allowed_repeats": ["X"],
    "strict_mode": true,
    "changes": [{
      "type": "insert",
      "start": 60,
      "end": 61,
      "sequence": "CCC"
    }],
    "type": "synthetic",
    "citation": null,
    "metadata": {
      "clinical_name": "synthetic",
      "pathogenicity": "benign",
      "frameshift": false,
      "frequency": "N/A (synthetic)",
      "description": "In-frame 3bp insertion in C-stretch. Tests variant caller specificity.",
      "benchmarking_category": "true_negative"
    }
  }
}
```

---

## 6. Benchmarking Strategy

### 6.1 Sensitivity Testing (True Positives)

**Objective:** Can variant callers detect **all pathogenic mutations**?

**Test Set:**
- dupC (common, 93%)
- dupA (rare, 3%)
- insG (rare, 2%)
- delinsAT (very rare, 1%)
- insC_pos41 (novel)
- ins16bp (novel)
- Various synthetic +1, +2, -1, -2 frameshift mutations
- Mutations at different VNTR positions
- Mutations in different repeat types (X, A, B)

**Metrics:**
- Sensitivity per mutation type
- Sensitivity vs VNTR length
- Sensitivity vs repeat structure complexity
- False negative rate

### 6.2 Specificity Testing (True Negatives)

**Objective:** Can variant callers distinguish **benign from pathogenic**?

**Test Set:**
- In-frame insertions in C-stretch (+3, +6, +9)
- In-frame deletions in C-stretch (-3, -6)
- In-frame indels outside C-stretch
- Silent SNPs
- Complex in-frame compound mutations
- Natural VNTR length polymorphism (via different `--fixed-lengths`)

**Metrics:**
- Specificity per variant type
- False positive rate
- Confusion matrix: pathogenic vs benign C-stretch mutations

### 6.3 Challenging Variant Caller Scenarios

**Scenario 1: Homopolymer Discrimination**
- dupC (+1, pathogenic) vs insCCC (+3, benign)
- dupCC (+2, pathogenic) vs insCCCCC (+5, pathogenic) vs insCCCCCC (+6, benign)
- Tests: Can callers accurately determine insertion length in 7C tract?

**Scenario 2: Position Sensitivity**
- Same mutation (e.g., insC) at different positions (27 vs 41)
- Tests: Can callers detect mutations outside canonical hotspot?

**Scenario 3: Complex Indels**
- delinsAT (pathogenic, -2+2=0 but frameshift if not same reading frame position)
- vs delins3bp_benign (in-frame replacement)
- Tests: Can callers correctly interpret complex variants?

**Scenario 4: Compound Mutations**
- Two mutations in same haplotype
- One pathogenic + one benign
- Tests: Phasing and compound variant calling

**Scenario 5: VNTR Length Dependency**
- Same mutation in short VNTR (20 repeats) vs long VNTR (120 repeats)
- Tests: Does VNTR length affect sensitivity?

### 6.4 Proposed Benchmarking Experiments

**Experiment 1: Pathogenic Variant Detection**
```bash
# Generate 20 haplotypes with different pathogenic mutations
for mutation in dupC dupA insG delinsAT insC_pos41; do
  muconeup --config config.json simulate \
    --out-base bench_pathogenic_${mutation} \
    --fixed-lengths 60 \
    --mutation-name ${mutation} \
    --mutation-targets 1,25
done

# Simulate reads
# Run variant callers (VNtyper, SharkVNTyper, etc.)
# Calculate sensitivity
```

**Experiment 2: Benign Variant Filtering**
```bash
# Generate 20 haplotypes with benign mutations
for mutation in insCCC_benign insCCCCCC_benign delCCC_benign; do
  muconeup --config config.json simulate \
    --out-base bench_benign_${mutation} \
    --fixed-lengths 60 \
    --mutation-name ${mutation} \
    --mutation-targets 1,25
done

# Simulate reads
# Run variant callers
# Calculate specificity (should NOT call as pathogenic)
```

**Experiment 3: Mixed Dataset (Ground Truth)**
```bash
# Create CSV with ground truth labels
# mutation_id, pathogenic (True/False), frameshift (True/False), position, type
# Generate all mutations
# Simulate reads
# Run callers
# Calculate precision, recall, F1 score
```

**Experiment 4: C-Stretch Discrimination**
```bash
# Generate series: dupC, dupCC, insCCC, insCCCC, insCCCCC, insCCCCCC
# All in same genomic context (C-stretch)
# Only dupC, dupCC, insCCCC, insCCCCC are pathogenic (+1, +2, +4, +5)
# insCCC and insCCCCCC are benign (+3, +6)
# Tests homopolymer discrimination accuracy
```

---

## 7. Literature Integration & Citation

### 7.1 Key Papers to Reference

1. **Kirby et al., Nature Genetics 2013**
   - "Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1"
   - First identification of MUC1 VNTR mutations in ADTKD

2. **Olinger et al., 2020s**
   - Identified 4 main mutations: 27dupC (93.5%), 28dupA (3.2%), 26_27insG (2%), 23delinsAT (1%)
   - Large cohort study (93 families)

3. **Živná et al., Scientific Reports 2018**
   - "Single molecule real time sequencing in ADTKD-MUC1"
   - SMRT sequencing for complete VNTR assembly and mutation positioning

4. **Saei et al., iScience 2023**
   - "VNtyper enables accurate alignment-free genotyping of MUC1 coding VNTR"
   - VNtyper tool development and validation

5. **Vrbacká et al., bioRxiv 2025**
   - "Long-Read Sequencing of the MUC1 VNTR"
   - 9 distinct frameshift mutation types identified
   - 205 unique VNTR alleles characterized
   - Novel variants: 41insC, 16bp insertion

6. **Danish Study (Clinical Kidney Journal 2025)**
   - MUC1-associated ADTKD prevalence in kidney failure cohort
   - Novel 16bp insertion characterized
   - VNtyper validation

### 7.2 Reference Database

**Create:** `mutations_literature_references.md`
- Table of all mutations
- PubMed IDs
- Clinical significance
- Allele frequencies
- Population data

---

## 8. Technical Considerations

### 8.1 Repeat Type Specificity

**Question:** Should all mutations be limited to "X" repeat only?

**Observations from config:**
- Most current mutations target "X" repeat
- Clinical literature focuses on specific VNTR units
- Different repeat types (A, B, C, etc.) have sequence variation

**Recommendations:**
1. **Primary mutations (clinical):** Target "X" repeat (`allowed_repeats: ["X"]`)
2. **Extended testing:** Create variants for other repeats to test different sequence contexts
3. **Use `strict_mode: true`** for clinical mutations to prevent auto-conversion

### 8.2 Multiple Mutations in Same Haplotype

**Current system supports:**
- Dual simulation: normal + mutated
- Multiple targets: `--mutation-targets 1,25 2,30`

**Enhancement opportunities:**
1. **Compound heterozygous simulation:**
   - Different mutations on each haplotype
   - Tests phasing accuracy

2. **Multiple mutations per haplotype:**
   - Pathogenic + benign on same allele
   - Tests compound variant calling

### 8.3 SNP Integration

**Current system supports:**
- Random SNPs: `--random-snps --random-snp-density 1.0`
- SNP file: `--snp-file snps.tsv`

**Enhancement for benchmarking:**
1. **Background SNPs + mutation:**
   - Realistic genomic context
   - Tests variant caller filtering

2. **SNPs near mutation site:**
   - Tests local haplotype reconstruction

### 8.4 ORF Prediction & Toxic Protein Detection

**Validation mechanism:**
1. For each mutation, run ORF prediction
2. Pathogenic mutations should produce:
   - Frameshift ORF
   - Novel amino acid sequence
   - Toxic protein markers (if `toxic_protein_detector.py` can detect)
3. Benign mutations should produce:
   - Normal ORF
   - No frameshift

**Automation:**
```bash
# After generating mutation
muconeup --config config.json simulate \
  --out-base test_mutation \
  --mutation-name dupC \
  --output-orfs \
  --orf-min-aa 100

# Check if ORF is frameshift (pathogenic) or normal (benign)
```

---

## 9. Action Items & Timeline

### Phase 1: Position Mapping & Validation (Week 1)
- [ ] Analyze X repeat sequence to identify 7C tract position
- [ ] Map literature positions to MucOneUp coordinates
- [ ] Create position mapping reference table
- [ ] Validate existing mutations against clinical nomenclature
- [ ] Document current mutation positions

### Phase 2: Update Existing Mutations with Citations (Week 1)
- [ ] Update dupC with Kirby 2013 + Olinger 2020 citations (type: "real", frequency: 93.5%)
- [ ] Update insCCCC metadata - change from synthetic to REAL (Vrbacká 2025, 56_59dupCCCC, 1 family)
- [ ] Update dupA with Olinger 2020 + Vrbacká 2025 citations (type: "real", frequency: 3.2%)
- [ ] Update insG with Olinger 2020 citation (type: "real", 26_27insG, frequency: 2.2%)
- [ ] Update delinsAT with Olinger 2020 citation (type: "real", 23delinsAT, frequency: 1.1%)
- [ ] Mark bigDel as type: "synthetic" with note: "Large deletion test mutation"
- [ ] Mark snpA_testing as type: "synthetic" with note: "SNP replacement test mutation"

### Phase 3: Implement New Pathogenic Mutations from Vrbacká 2025 (Week 1-2)
- [ ] Implement insC_pos23 (A:/E:23dupC, 2 families)
- [ ] Implement insG_pos58 (B:/X:58_59insG, 2 families)
- [ ] Implement insG_pos54 (bJ:54_55insG, 1 family)
- [ ] Implement insA_pos54 (aH:54_55insA, 1 family)
- [ ] Implement del18_31 (X:18_31del, 1 family)
- [ ] Implement ins16bp (C:42_57dupGGGCTCCACCGCCCCC, 1 family) - 16bp duplication at positions 42-57

### Phase 4: Implement Benign Mutations - ONLY 4 (Week 2)
- [ ] Implement insCCC_benign (+3 in C-stretch)
- [ ] Implement insCCCCCC_benign (+6 in C-stretch)
- [ ] Implement delCCC_benign (-3 in C-stretch)
- [ ] Implement del3bp_pos30_benign (-3 outside C-stretch)
- [ ] **NO additional benign mutations** - keep it simple and focused

### Phase 5: ORF Validation & Testing (Week 2-3) - CRITICAL
- [ ] Generate test sequences for ALL pathogenic mutations (8 total)
- [ ] Generate test sequences for ALL benign mutations (4 total)
- [ ] Run ORF prediction on all mutations with `--output-orfs --orf-min-aa 50`
- [ ] **Verify frameshift status for each mutation**:
  - Pathogenic: MUST show frameshift in ORF analysis
  - Benign: MUST NOT show frameshift in ORF analysis
- [ ] Document validation results in `validation_results.tsv`
- [ ] Create test simulations for each mutation
- [ ] **FLAG any mutations that fail validation** (frameshift status doesn't match expected)

### Phase 6: Benchmarking Infrastructure (Week 4)
- [ ] Create ground truth CSV file
- [ ] Design benchmarking experiment protocols
- [ ] Implement read simulation pipeline for all mutations
- [ ] Create variant caller evaluation scripts
- [ ] Generate initial benchmarking dataset

---

## 10. Expected Outcomes

### 10.1 Mutation Database

**Deliverable:** Extended `config.json` with:
- **11 real pathogenic mutations** from literature:
  - 3 existing verified (dupC, dupA, insG) with citations added
  - 2 existing corrected (insCCCC confirmed as real, delinsAT verified)
  - 6 NEW to implement (insC_pos23, insG_pos58, insG_pos54, insA_pos54, del18_31, ins16bp)
- **6 synthetic testing mutations**:
  - 2 existing (bigDel, snpA_testing) - mark as type: "synthetic"
  - 4 NEW benign for specificity testing (insCCC_benign, insCCCCCC_benign, delCCC_benign, del3bp_pos30_benign)
- **Complete metadata** for each mutation:
  - `type`: "real" or "synthetic"
  - `citation`: Full citation with DOI/PMID (or null for synthetic)
  - Clinical names, frequencies, pathogenicity
- **Literature references**:
  - Kirby et al. 2013 (Nat Genet) - first MUC1 VNTR mutation discovery
  - Olinger et al. 2020 (Kidney Int) - 4 main mutations with frequencies
  - Vrbacká et al. 2025 (bioRxiv) - 9 mutation types in 52 alleles

### 10.2 Benchmarking Dataset

**Deliverable:** Simulated VNTR sequences with:
- Known ground truth labels
- Mixed pathogenic and benign variants
- Multiple VNTR lengths and structures
- Paired FASTA + BAM + VCF (after read simulation)

### 10.3 Documentation

**Deliverable:**
- `mutations_literature_references.md` - Citation database
- `mutation_benchmarking_guide.md` - How to use mutations for testing
- Updated `CLAUDE.md` with mutation details
- Position mapping reference table

### 10.4 Validation Reports - ORF Analysis (CRITICAL)

**Deliverable:**
- **`validation_results.tsv`** - Complete ORF validation for all 12 mutations:
  - Expected vs observed frameshift status
  - PASS/FAIL validation status
  - Notes on any discrepancies
- **ORF prediction results** for all mutations (FASTA format)
- **Frameshift classification report** comparing pathogenic vs benign
- **Toxic protein detection results** (if toxic_protein_detector is available)
- **Test simulation outputs** (FASTA, structure files, stats JSON)

**Critical Success Criteria:**
- ALL 8 pathogenic mutations MUST show frameshift in ORF analysis
- ALL 4 benign mutations MUST NOT show frameshift in ORF analysis
- Any failures must be investigated and mutations corrected

---

## 11. Future Enhancements

### 11.1 Retrieve Full Vrbacká Catalog

**Goal:** Access bioRxiv preprint 2025.09.06.673538 to extract:
- All 9 frameshift mutation types
- Exact sequences and positions
- Allele frequency data
- Additional novel variants

**Method:**
- Request PDF through institutional access
- Contact authors for supplementary data
- Check if paper is published in peer-reviewed journal

### 11.2 Population Genetics

**Enhancement:**
- Add population-specific allele frequencies
- Implement founder mutations
- Geographic variant distribution

### 11.3 Advanced Benign Variants

**Enhancement:**
- Missense mutations in VNTR
- In-frame repeat number variation (simulate +1 repeat unit = +60bp)
- Regulatory variants (if MucOneUp extends to flanking regions)

### 11.4 Machine Learning Training Data

**Enhancement:**
- Generate large-scale simulated dataset
- Train ML models to distinguish pathogenic vs benign
- Feature extraction from sequence context

---

## 12. Questions & Uncertainties

### 12.1 Critical Questions to Resolve

1. **Position mapping:**
   - What is the exact position of the 7C tract in the MucOneUp X repeat?
   - How do MucOneUp positions map to clinical nomenclature?

2. **16bp insertion:**
   - What is the exact sequence of the 16bp insertion?
   - At what position does it occur?

3. **Silent mutations:**
   - Which positions in X repeat are synonymous?
   - Need codon table analysis

4. **Repeat type specificity:**
   - Should mutations be implemented for all repeat types (A, B, C, etc.)?
   - Or just X as primary target?

5. **Validation:**
   - How to programmatically verify frameshift vs in-frame?
   - Can `toxic_protein_detector.py` detect MUC1fs?

### 12.2 Data Needs

1. **Full text access:**
   - Vrbacká et al. bioRxiv 2025 (currently blocked)
   - Supplementary tables with all mutation sequences

2. **Clinical databases:**
   - ClinVar entries for MUC1 variants
   - HGMD (Human Gene Mutation Database)
   - UniProt MUC1 variant annotations

3. **VNtyper reference:**
   - VNtyper mutation catalog
   - Expected outputs for known mutations

---

## 13. Conclusion

This plan provides a **focused, evidence-based roadmap** for extending MucOneUp's mutation system with:

1. **11 real pathogenic mutations** from literature (5 existing verified, 6 NEW from Vrbacká 2025)
2. **6 synthetic testing mutations** (2 existing marked as synthetic, 4 NEW focused benign)
3. **Complete citation metadata** (type: real/synthetic, full citations with DOI/PMID)
4. **Mandatory ORF validation** to verify frameshift status for all mutations
5. **Systematic benchmarking framework** to evaluate variant calling tools

**Key Revisions from Original Plan:**
- **Reduced from 15-20 to 4 NEW benign mutations** - less is more, focused on critical tests
- **insCCCC is REAL, not synthetic** - confirmed as 56_59dupCCCC in Vrbacká 2025 (1 family)
- **ins16bp corrected** - exactly 16 bases (C:42_57dupGGGCTCCACCGCCCCC) at positions 42-57
- **All mutations mapped from preprint** - exact positions, repeat units, and frequencies
- **Citation tracking** - every real mutation has proper literature reference (Kirby 2013, Olinger 2020, Vrbacká 2025)
- **ORF validation is mandatory** - pathogenic MUST frameshift, benign MUST NOT
- **Existing test mutations retained** - bigDel and snpA_testing marked as synthetic

**Key Success Factors:**
1. **ORF validation of frameshift status** (CRITICAL - all mutations must pass)
2. Accurate position mapping using existing dupC as reference
3. Complete metadata with type and citation fields
4. Systematic benchmarking experiments

**Next Steps:**
1. Update existing mutations with citations and type field
2. Implement 6 new pathogenic mutations from Vrbacká 2025
3. Implement 4 focused benign mutations
4. **RUN ORF VALIDATION ON ALL 12 MUTATIONS** (most critical step)
5. Document validation results
6. Design and execute benchmarking experiments

---

## Appendices

### Appendix A: MUC1 VNTR Structure Reference

```
60bp Canonical Repeat Unit (from config.json):
Position:  0         10        20        30        40        50        60
X repeat:  GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCCCCCCA
           |                        |                        |
           Start                    Middle                   End (7C?)

Sequence features:
- High GC content (>80%)
- Homopolymer tracts: C-stretch at end
- Translation: 20 amino acid repeat
```

### Appendix B: Frameshift Mutation Examples

```
Wild-type (reading frame 0):
GCC CAC GGT GTC ACC TCG GCC CCG GAC ACC AGG CCG GCC CCG GGC TCC ACC GCC CCC CCA
Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro

Pathogenic dupC (+1 frameshift):
GCC CAC GGT GTC ACC TCG GCC CCG GAC ACC AGG CCG GCC CCG GGC TCC ACC GCC CCC CCC A
GC CCA CGG TGT CAC CTC GGC CCC GGA CAC CAG GCC GGC CCC GGG CTC CAC CGC CCC CCC CA
[Frame +1 - creates novel protein MUC1fs]

Benign insCCC (+3 in-frame):
GCC CAC GGT GTC ACC TCG GCC CCG GAC ACC AGG CCG GCC CCG GGC TCC ACC GCC CCC CCC CCC CCA
Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Pro Pro
[Frame 0 maintained - just adds one codon (Pro)]
```

### Appendix C: Clinical Mutation Nomenclature

Multiple nomenclature systems exist:

| HGVS (cDNA) | HGVS (protein) | Position in 60bp | Alternative Names |
|-------------|----------------|------------------|-------------------|
| c.428dupC | p.Thr143HisfsTer21 | 27 or 59 | 27dupC, 59dupC, insC |
| c.429dupA | p.Thr143AsnfsTer? | 28 | 28dupA |
| c.427_428insG | p.Thr143? | 26-27 | 26_27insG |
| c.424_425delinsAT | p.? | 23-24 | 23delinsAT |

**Note:** Different papers use different reference sequences and coordinate systems.

---

## Appendix D: Complete Mutation Summary with Citations

| Mutation Name | Type | Position | Change | Frequency | Citation | Status |
|---------------|------|----------|--------|-----------|----------|--------|
| **dupC** | real | 60-61 | insC | 85-93.5% | Kirby 2013, Olinger 2020 | **EXISTING** |
| **dupA** | real | 60-61 | insA | 3.2% | Olinger 2020, Vrbacká 2025 | **EXISTING** |
| **insG** | real | 59-60 | insG | 2.2% | Olinger 2020 (26_27insG) | **EXISTING** |
| **delinsAT** | real | 54-56 | delinsAT | 1.1% | Olinger 2020 (23delinsAT) | **EXISTING** |
| **insCCCC** | real | 60-61 | insCCCC | 1 family | Vrbacká 2025 (56_59dupCCCC) | **EXISTING** - update metadata |
| **insC_pos23** | real | 23-24 | insC | 2 families | Vrbacká 2025 (A:/E:23dupC) | **NEW** |
| **insG_pos58** | real | 58-59 | insG | 2 families | Vrbacká 2025 (B:/X:58_59insG) | **NEW** |
| **insG_pos54** | real | 54-55 | insG | 1 family | Vrbacká 2025 (bJ:54_55insG) | **NEW** |
| **insA_pos54** | real | 54-55 | insA | 1 family | Vrbacká 2025 (aH:54_55insA) | **NEW** |
| **del18_31** | real | 18-32 | del 14bp | 1 family | Vrbacká 2025 (X:18_31del) | **NEW** |
| **ins16bp** | real | 57-58 | ins 16bp | 1 family | Vrbacká 2025 (C:42_57dup) | **NEW** |
| **bigDel** | synthetic | 1-26 | del 26bp | N/A | Large deletion test mutation | **EXISTING** - mark as synthetic |
| **snpA_testing** | synthetic | 2 | replace | N/A | SNP replacement test mutation | **EXISTING** - mark as synthetic |
| **insCCC_benign** | synthetic | 60-61 | insCCC | N/A | Designed for testing | **NEW** |
| **insCCCCCC_benign** | synthetic | 60-61 | insCCCCCC | N/A | Designed for testing | **NEW** |
| **delCCC_benign** | synthetic | 54-57 | delCCC | N/A | Designed for testing | **NEW** |
| **del3bp_pos30_benign** | synthetic | 30-33 | del 3bp | N/A | Designed for testing | **NEW** |

**Total: 17 mutations (11 real pathogenic + 6 synthetic testing)**
- Real pathogenic: 5 existing confirmed + 6 NEW to implement = **11 total**
- Synthetic testing: 2 existing (bigDel, snpA_testing) + 4 NEW benign = **6 total**

---

**Document Version:** 2.0
**Author:** Claude Code (AI Analysis)
**Date:** 2025-10-18
**Status:** REVISED - Citations added, section 3.2 reduced to 4 mutations, ORF validation added
